Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2023 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

The Prescrire Awards for 2022: no "Pilule d'Or" Awards, one drug on the "Honours List". Details in the March issue of Prescrire International This year, none of the drugs we examined represented a major therapeutic advance justifying a Pilule d'Or ("Golden Pill" Award). One drug made the Honours List, while one other was cited as Noteworthy. 1 March 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Negligence  Editorial  According to a World Health Organization (WHO) news release from 27 October 2022, almost 11 million people worldwide fell ill with tuberculosis in 2021, including about a million children. More than 1.5 million people died from tuberculosis. 1 March 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Oral vitamin D supplementation: dangerous overdoses caused by errors  Adverse Effects  Vitamin D overdose exposes patients to the risk of hypercalcaemia and hyperphosphataemia, and their sometimes serious or even fatal adverse effects, including: thirst, polyuria, anorexia, constipation, muscle weakness, fatigue, nausea and vomiting, confusion and renal disorders. Full article (3 pages) available for download by subscribers 1 March 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Empagliflozin (Jardiance°) in chronic heart failure   Marketing Authorisations  Given the absence of any comparison with other heart-failure drugs, empagliflozin has not been shown to represent a therapeutic advance. In particular, when the left ventricular ejection fraction is reduced, there is no evidence to suggest that empagliflozin offers any advantages over dapagliflozin. Full article (2 pages) available for download by subscribers 1 March 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Winners and losers   Marketing Authorisations  In the European Union, it has been possible since the mid-2000s for a drug's marketing authorisation to be conditional, i.e. granted on condition that the company subsequently provides data to justify full, standard marketing authorisation. The stated aim is commendable: hasten access to a drug in situations where no satisfactory options are available to patients and healthcare professionals. Full article (1 page) available for download by subscribers 1 March 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Risankizumab (Skyrizi°) in psoriatic arthritis • Eszopiclone (Noxiben°) in insomnia • Ibrutinib: increased risk of sudden death • Melatonin poisoning in children:sometimes serious • Prescrire's ratings of new drugs in 2022: a brief review  > Subscribe now 1 March 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 January 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "Top Texts of 2022", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this sampling of texts from Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Inside, top articles from sections dedicated to new drugs authorised in Europe and key information on adverse drug effects, plus our annual update of drugs to avoid. > Click here for your free copy 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2023 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page